Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 38.4% in February

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 148,000 shares, a growth of 38.4% from the February 13th total of 106,900 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 0.1 days. Approximately 5.4% of the company’s stock are short sold.

Palisade Bio Trading Up 9.0 %

NASDAQ PALI traded up $0.08 during trading on Friday, reaching $1.00. The company’s stock had a trading volume of 1,454,422 shares, compared to its average volume of 758,972. The stock has a market capitalization of $2.77 million, a PE ratio of -0.07 and a beta of 1.49. The business has a 50-day moving average price of $1.27 and a 200-day moving average price of $2.30. Palisade Bio has a 1-year low of $0.75 and a 1-year high of $9.65.

Institutional Trading of Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. bought a new stake in Palisade Bio, Inc. (NASDAQ:PALI) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned about 0.54% of Palisade Bio as of its most recent SEC filing. 11.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management initiated coverage on shares of Palisade Bio in a research report on Wednesday, November 20th. They set a “buy” rating and a $38.00 price objective on the stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.